To reduce mortality, current guidelines recommend beta-blockers, ACE-I, AT, AT-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-dependent glucose transporter (SGLT2) inhibitors for all patients with stable, symptomatic heart failure with reduced LVEF [4]. This evidence concerns the gene SLC5A2 and heart failure.